Literature DB >> 17854311

Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.

Alberto Fabbri1, Mariapia Lenoci, Alessandro Gozzetti, Ida Chitarrelli, Francesca Olcese, Donatella Raspadori, Marco Gobbi, Francesco Lauria.   

Abstract

Twenty-five elderly patients with untreated indolent non-Hodgkin lymphoma were treated with oral fludarabine 25 mg/m(2)/d (40 mg total dose) and cyclophosphamide 150 mg/m(2)/d, both for four consecutive days, repeated every 28 d for four cycles. In all, 21 (84%) patients were responsive: 10 patients achieved complete remission while partial response was obtained in 11. During an observation period of 37 months, there was an overall survival rate of 70% and a median event-free survival of 20 months. Haematological and extra-haematological toxicity were mild. This reduced-dose Flu-based oral regimen showed good efficacy and was simple to administer on an outpatient basis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854311     DOI: 10.1111/j.1365-2141.2007.06746.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  1 in total

1.  Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma.

Authors:  Jae-Sook Ahn; Deok-Hwan Yang; Sung-Hoon Jung; Soo-Young Bae; Huong Thi Thanh Tran; Hyung Chul Park; Ha-Na Kim; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Korean J Hematol       Date:  2011-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.